Many evidences suggest that atherosclerosis is an inflammatory disease and inflammatory markers can be an important prognostic factors in acute coronary syndrome. Hydroxymethylglutaryl (HMG-CoA) reductase inhibitors (statins) have been shown anti-inflammatory property that are independent of lipid-lowering effects. We evaluated the effects of 2-month treatment with simvastatin (40 mg/d, n=20) on plasma levels of circulating high-sensitivity C-reactive protein (hsCRP), inflammatory cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6], and adhesion molecules [p-selectin and monocyte chemotactic peptide (MCP)-1] with placebo group (n=20) in 40 normocholesterolemic patients (LDL＜130 mg/dl) with acute coronary syndrome. Simvastatin therapy significantly reduced plasma levels of total cholesterol and LDL-cholesterol (p=0.05, p=0.02, respectively) compared with placebo group. Simvastatin therapy also significantly reduced plasma levels of hsCRP and IL-6 (p=0.03, p=0.03, respectively) compared with placebo group. But, the reduction of hsCRP and IL-6 levels with simvastatin was unrelated to the degree of LDL-cholesterol's reduction. The effect of simvastatin on the reduction of hsCRP and IL-6, but not on the other inflammatory cytokines and adhesion molecules, have potential implications in the management of acute coronary syndrome with normocholesterolemia.
Introduction
Many lines of evidence suggest that atherosclerosis is an inflammatory disease and biomarkers of inflammation could be an important prognostic factors in acute coronary syndrome. 1−9 Statins are main drugs to reduce plasma levels of total cholesterol and LDL-cholesterol and confirm clinical benefits from primary and secondary prevention trials. 10−12 Recently, these agent have been shown to reduce atherosclerotic cardiovascular mortality and morbidity via pleiotropic effects including an anti-inflammatory, anti-thrombotic, and anti-oxidant action that are independent of lipid-lowering effects in hypercholesterolemic patients. 13−15 But, little has been known that the effect of statin on systemic inflammation
with subsequent left ventricular function in normocholesterolemic patients with acute ccoronary syndrome.
This study was designed to document the effect of statin on the variety of inflammatory markers and left 
Materials and Methods
The treatment plan and investigations were designed in accordance with the guidelines of the local ethical committee (Chonnam National University Hospital).
We evaluated the effect of 2-month treatment with Transthoracic echocardiogram was performed before and 2 months after treatment with simvastatin or placebo.
And left ventricular (LV) end-diastolic and end-systolic dimension, LV mass, LV volumes, and LV ejection fraction were determined.
Statistics
For the statistical analysis, the unpaired t-test and
Chi-square test were performed using SPSS-PC 11.0 (Statistical package for the social sciences, SPSS-PC Inc. Chicago, IL, USA) and the values were designed as mean±standard error. A value of P less than 0.05 was considered as significant.
Results
The baseline characteristics of the study population are given in Table 1 . No significant differences were observed between the groups. hsCRP, High-sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α; IL-1β, interleukin -1β; IL-6, interleukin-6; MCP-1, monocyte chemotactic peptide -1. *p＜0.05, Changes (Δ) in the profiles after 2 months of simvastatin treatment vs. placebo T-chol, total cholesterol; LDL-chol: low density lipoprotein-cholesterol; HDL-chol, high density lipoprotein-cholesterol; TG, triglyceride. *p＜0.05, Changes (Δ) in the profiles after 2 months of simvastatin treatment vs. placebo were less pronounced ( Table 2) .
Simvastatin therapy significantly reduced the hsCRP (Table 3) . The LV endsystolic and end-diastolic dimensions, LV mass, and LV ejection fraction were not changed significantly after simvastatin treatment when compared with placebo group (Fig. 1 ).
Discussion
Our understanding of the mechanisms underlying Aggressive statin therapy have reduced the hsCRP levels in the patients with hypercholesterolemia and extent of hs-CRP reduction is associated with the progression rate of the atherosclerotic process. 16 Li et al. 17 demonstrated that CRP could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner. Some animal experiments reported that statin therapy profoundly changed the LV remodeling after myocardial infarction. 18, 19 This study demonstrated that 2-months simvastatin treatment decreased hsCRP and IL-6 in normocholesterolemic patients with acute coronary syndrome. For the elucidation of pleotropic effects by statin such as anti-inflammation, 2-months interval is sufficient. Simvastatin therapy did not change significantly LV remodeling in short period even though the LV end-diastolic dimension inclined to decrease with simvastatin treatment. Long-term follow-up of the effect of statin on the LV remodeling has to be determined.
In summary, this study showed simvastatin reduced hsCRP and IL-6 levels in normocholesterolemic patients with acute coronary syndrome. The effect of simvastatin on hsCRP and IL-6 levels was independent of lipid lowering efficacy.
